Menu Search
Equities

1933 Industries Inc

TGIFF:QBB

1933 Industries Inc

Actions
  • Price (USD)0.0143
  • Today's Change0.004 / 34.27%
  • Shares traded62.46k
  • 1 Year change+10.00%
  • Beta--
Data delayed at least 15 minutes, as of May 20 2024 17:58 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

1933 Industries Inc. is a Canada-based cannabis cultivator and producer. The Company is focused on the cultivation and manufacturing of a portfolio of cannabis consumer-packaged goods in a variety of formats for both the wholesale and retail markets. Its product offerings through its in-house brands, including wholesale flower, pre-rolls, and extracted products under the AMA and Level X brands for the Nevada market; and Canna Hemp, a national cannabidiol (CBD) brand of wellness products, which include tinctures, gummies, topicals and sports recovery products. The Company owns 91% of Alternative Medicine Association, LC (AMA) and 100% of Infused MFG LLC (Infused). AMA is a licensed medical and adult-use cannabis cultivation and extraction company, which produced its own AMA branded line of cannabis-based products and manufactures third-party brands. Infused produces the Canna Hemp line of hemp-based, CBD products. Infused’s product line includes topicals, creams, vapes and others.

  • Revenue in CAD (TTM)19.27m
  • Net income in CAD-13.06m
  • Incorporated2018
  • Employees87.00
  • Location
    1933 Industries IncSuite 300, 1055 West Hastings StreetVANCOUVER V6E 2E9CanadaCAN
  • Phone+1 (604) 674-4756
  • Websitehttps://1933industries.com
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.